Last reviewed 2026-04-19 · How we verify

Lenzumestrocel

Corestemchemon, Inc. · Phase 3 active Biologic

Lenzumestrocel is a Biologic drug developed by Corestemchemon, Inc.. It is currently in Phase 3 development. Also known as: Neuronata-R inj, Autologous Bone Marrow derived Mesenchymal Stem Cell, Neuronata-R, Autologous Bone Marrow derived Mesenchymal Stem cell.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Lenzumestrocel
Also known as	Neuronata-R inj, Autologous Bone Marrow derived Mesenchymal Stem Cell, Neuronata-R, Autologous Bone Marrow derived Mesenchymal Stem cell
Sponsor	Corestemchemon, Inc.
Modality	Biologic
Therapeutic area	Other
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lenzumestrocel CI brief — competitive landscape report
Lenzumestrocel updates RSS · CI watch RSS
Corestemchemon, Inc. portfolio CI

Frequently asked questions about Lenzumestrocel

What is Lenzumestrocel?

Lenzumestrocel is a Biologic drug developed by Corestemchemon, Inc..

Who makes Lenzumestrocel?

Lenzumestrocel is developed by Corestemchemon, Inc. (see full Corestemchemon, Inc. pipeline at /company/corestemchemon-inc).

Is Lenzumestrocel also known as anything else?

Lenzumestrocel is also known as Neuronata-R inj, Autologous Bone Marrow derived Mesenchymal Stem Cell, Neuronata-R, Autologous Bone Marrow derived Mesenchymal Stem cell.

What development phase is Lenzumestrocel in?

Lenzumestrocel is in Phase 3.

Manufacturer: Corestemchemon, Inc. — full pipeline
Therapeutic area: All drugs in Other
Also known as: Neuronata-R inj, Autologous Bone Marrow derived Mesenchymal Stem Cell, Neuronata-R, Autologous Bone Marrow derived Mesenchymal Stem cell

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing